To continue strengthening international healthcare cooperation and keep abreast of the latest developments in liver disease treatment worldwide, Taiwan Green Cross General Manager Lin Tsai-ling led a company delegation and representatives of domestic clinicians to Beijing from March 26 to 30, 2025, to take part in an international academic exchange in which GRIFOLS — a global leader in plasma protein therapies — participated: APASL Annual Meeting 2025 (Asian Pacific Association for the Study of the Liver), together taking part in exhibition-booth displays and professional exchange, demonstrating the positive results of Taiwan's healthcare industry connecting with the world.
Held during a major Asian academic event on liver disease, the meeting drew hepatobiliary and gastroenterology specialists, transplant medicine teams and healthcare industry representatives from Asia, Europe and North America, who together discussed the latest clinical evidence and treatment strategies in areas such as cirrhosis, liver failure, liver transplantation and critical care.
In-depth Exchange with the GRIFOLS Global Team
During the event, in addition to in-depth exchange with GRIFOLS's global and Asia-Pacific executives, the Taiwan Green Cross team held academic discussions with experts and scholars from medical centers across the Taiwan Strait and internationally, sharing experience and exchanging views on the clinical application of albumin in the treatment of cirrhosis, ascites, hepatorenal syndrome and critically ill patients.
Remarks from General Manager Lin Tsai-ling
Healthcare has entered an era of globalization. By taking part in international academic conferences and cross-border industry exchange, we can not only keep abreast of the latest treatment trends but also bring international clinical evidence and innovative treatment concepts to Taiwan, helping medical teams provide patients with more comprehensive quality of care. Being able to exchange with the GRIFOLS global team and experts from around the world holds important significance for future clinical education and market development.
Exhibition Exchange and Future Outlook
In addition to the academic forums, the team also took part in GRIFOLS's exhibition-area activities, introducing the latest developments in the relevant treatment fields to attending experts and healthcare professionals, further deepening international cooperation and establishing opportunities for future regional healthcare exchange and clinical research collaboration.
As a major company in the global field of plasma protein therapies, GRIFOLS has long invested in the research and development of albumin, immunoglobulin, coagulation factor and critical-care products, with a strong clinical foundation and international influence in liver disease and critical care.
Taiwan Green Cross stated that it will continue to support domestic physicians in participating in international academic activities, actively promote cooperation with international healthcare institutions and industry partners, help Taiwan's healthcare system stay aligned with the latest global healthcare trends, and together improve patient treatment quality and care outcomes.
